Stroke, Acute
Conditions
Brief summary
The study investigates the effect of plasma myeloperoxidase (MPO) concentrations on HDL dysfunction during the acute stage of ischemic and haemorrhagic strokes.
Detailed description
MRI or CT scan are used to confirm the diagnosis of haemorrhagic, ischemic and mimick stroke. Plasma anf HDL-MPO concentrations, as well as potent HDL dysfunction, are compared in the 3 cases. The investigators hypothesis is that MPO concentrations and subsequent HDL dysfunction could be higher in ischemic strokes than in haemorrhagic ones. MPO could be a examined as a potent marker of early stage of ischemic stroke. Plasma MPO levels could also be discriminant regarding the mimick strokes in patient exhibiting stroke clinical picture.
Interventions
OTHERIschemic stroke
Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
OTHERHaemorrhagic stroke
Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Centre Hospitalier Universitaire de la Réunion
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients with less than 12 hours stroke clinical signs: * hemiparesis or hemiplegia * unilateral sensitivity disorder * language impairment * balance disorder * dizziness, bilateral or monocular vision totally or partially lost
Exclusion criteria
* Pregnancy * head trauma since the last 3 months * stroke since the last 3 months * myocardial infarction since the last 3 months * patient disagrees to be enrolled in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma MPO concentrations | Through study completion, an average of 6 hours | Assessment of plasma MPO concentrations during acute stage of stroke |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HDL-MPO concentrations | Through study completion, an average of 6 hours | Assessment of HDL-MPO concentrations during acute stage of stroke |
Other
| Measure | Time frame | Description |
|---|---|---|
| HDL dysfunction | Through study completion, an average of 6 hours | Assessment of HDL function using inhibition test on cell culture |
Countries
Reunion
Contacts
Primary ContactChristine JUHEL, PHD
Backup ContactDavid COURET, MD
Outcome results
None listed